OBJECTIVE: To evaluate the efficacy of CyberKnife (Accuray, Inc., Sunnyvale, CA) stereotactic radiosurgery (SRS) for @entity1 with brain metastases of @entity320 and @entity1358 . METHODS: We conducted a retrospective review of all @entity1 treated by image-guided radiosurgery at our institution between March 1999 and December 2005. Sixty-two @entity1 with 145 brain metastases of @entity1358 or @entity320 were identified. RESULTS: The median follow-up period was 10.5 months. Forty-four @entity1 had @entity320 , and 18 @entity1 had @entity1358 . The median age was 57 years, and @entity1 were classified as recursive partitioning analysis Class 1 (6 @entity1 ), 2 (52 @entity1 ) or 3 (4 @entity1 ). Thirty-three @entity1 had been treated systemically with either chemotherapy or immunotherapy, and 33 @entity1 were taking corticosteroids at the time of treatment. The mean @entity5 volume was 1.47 mL (range, 0.02-35.7 mL), and the mean prescribed dose was 20 Gy (range, 14-24 Gy). The median survival after SRS was 8.3 months. Actuarial survival at 6 and 12 months was 57 and 37%, respectively. On multivariate analysis, Karnofsky Performance Scale score (P < 0.01) and previous immunotherapy/clinical trial (P = 0.01) significantly affected overall survival. One-year intracranial progression-free survival was 38%, and local control was 87%. Intracranial control was impacted by whole-brain radiotherapy (P = 0.01), previous chemotherapy (P = 0.01), and control of the primary at the time of SRS (P = 0.02). Surgical resection had no effect on intracranial or local control. Radiographic evidence of radiation @entity39 developed in 4 @entity1 (6%). CONCLUSION: CyberKnife radiosurgery provided excellent local control with acceptable @entity137 in @entity1 with @entity320 or renal cell brain metastases. Initial SRS alone appeared to be a reasonable option, as survival was dictated by @entity262 .

Cyberknife for brain metastases of XXXX and @entity1358 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity262 :: ('MESH:D034721', 'Disease') :: ['systemic disease'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'malignant melanoma']
@entity320 :: (MESH:D008545,Disease) :: ['malignant melanoma']
